Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1 9Phase 3 4Phase 4 2Phase 2/3 1Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Plasma cell 1

Conditions

Waldenstrom Macroglobulinemia 2Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, B-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Graft vs Host Disease 1

Interventions

zanubrutinib 2ibrutinib 2talquetamab 1Thiotepa 1Thalidomide 1Sirolimus 1Rituximab 1Radiotherapy 1Prednisone 1Filgrastim 1Everolimus 1Cyclophosphamide 1Bortezomib 1Antilymphocyte Serum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Waldenstrom Macroglobulinemia × ibrutinib × Clear all
NCT07474961 2026-03-16

BLOOD-dose

Rigshospitalet, Denmark

Phase 4 Not yet recruiting
400 enrolled
LymphoidPlasma cell

Waldenstrom Macroglobulinemia, Multiple Myeloma

NCT04042376 2025-05-25

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Janssen Research & Development, LLC

Phase 4 Completed
17 enrolled 15 charts
Lymphoid

Waldenstrom Macroglobulinemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡